ROBIOS

Robios is a preclinical-stage biotechnology company focused on developing novel therapies for fibrotic diseases by targeting the Slit/Robo signaling pathway. The company was founded based on research from the University of California, San Francisco, which identified Roundabout (Robo) receptors as key regulators of myofibroblast activity and tissue scarring. Their therapeutic approach aims to inhibit the pathological activation of fibroblasts to treat conditions such as Idiopathic Pulmonary Fibrosis and chronic kidney disease. By leveraging deep expertise in cell biology and guidance molecules, Robios is building a pipeline of first-in-class inhibitors to address high unmet medical needs in organ fibrosis. The company is backed by leading life science venture capital firms and continues to advance its proprietary platform toward clinical entry.